Mechanisms of Involvement of Eicosanoids and their Precursors in the Pathophysiology and Treatment of Schizophrenia

By  

Medicinal Chemistry, Vol. 9, Iss. 6, 2013-09 ,pp. : 763-773

Bentham Science Publishers

Access to resources Recommend Favorite

The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications

By Harrison Paul  

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 151-162

Springer Publishing Company

Access to resources Recommend Favorite

Evidence for the involvement of cannabinoid receptors' polymorphisms in the pathophysiology of human diseases

By Vasileiou Ioanna   Fotopoulou Georgia   Matzourani Marina   Patsouris Efstratios   Theocharis Stamatios  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 4, 2013-04 ,pp. : 363-377

Informa Healthcare

Access to resources Recommend Favorite

Glutamate and Schizophrenia: Pathophysiology and Therapeutics

By  

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 2, Iss. 1, 2002-03 ,pp. : 29-44

Bentham Science Publishers

Access to resources Recommend Favorite

The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment

By  

Current Neuropharmacology, Vol. 12, Iss. 3, 2014-05 ,pp. : 219-238

Bentham Science Publishers

Access to resources Recommend Favorite